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ABSTRACT
Poly(ADP-ribose) (pADPr) is a polymer assembled
from the enzymatic polymerization of the ADP-
ribosyl moiety of NAD by poly(ADP-ribose) poly-
merases (PARPs). The dynamic turnover of pADPr
within the cell is essential for a number of cellular
processes including progression through the cell
cycle, DNA repair and the maintenance of genomic
integrity, and apoptosis. In spite of the considerable
advances in the knowledge of the physiological
conditions modulated by poly(ADP-ribosyl)ation
reactions, and notwithstanding the fact that pADPr
can play a role of mediator in a wide spectrum of
biological processes, few pADPr binding proteins
have been identified so far. In this study, refined
in silico prediction of pADPr binding proteins and
large-scale mass spectrometry-based proteome
analysis of pADPr binding proteins were used
to establish a comprehensive repertoire of pADPr-
associated proteins. Visualization and modeling
of these pADPr-associated proteins in networks
not only reflect the widespread involvement of
poly(ADP-ribosyl)ation in several pathways but also
identify protein targets that could shed new light
on the regulatory functions of pADPr in normal
physiological conditions as well as after exposure
to genotoxic stimuli.
INTRODUCTION
The activation of poly(ADP-ribose) polymerases (PARPs)
has been the subject of numerous studies in which
poly(ADP-ribose) (pADPr), a branched polymer assem-
bled upon the catalytic transfer of ADP-ribose moieties
from NAD, was initially regarded as a posttranslational
modiﬁcation. Indeed, the covalent attachment of pADPr
chains to chromatin-associated proteins, such as his-
tones has been known for decades (1). Since then, a grow-
ing body of work on pADPr metabolism across a broad
range of model systems has identiﬁed new pADPr-
associated proteins. Whether these proteins are covalently
poly(ADP-ribosyl)ated, noncovalent pADPr binding pro-
teins or exhibiting both properties, they can collectively
be termed pADPr-associated proteins. The methods used
so far to identify pADPr-associated proteins are sum-
marized in Figure 1. Current strategies include various
biochemical and biological validation approaches, bioin-
formatics analysis for the prediction of pADPr binding
motifs or in vivo cell imaging. In spite of the increas-
ing number of tools currently used to identify pADPr-
associated proteins, very little literature addresses the
question of poly(ADP-ribosyl)ation from a pADPr bind-
ing perspective. Until recently, most of the attention to
pADPr-associated proteins has been focused on covalent
poly(ADP-ribosyl)ation because of the drastic conse-
quences generally observed on protein properties (2).
However, several studies are now pointing to important
noncovalent interactions between pADPr and various
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are now known to bind in a noncovalent manner to
pADPr.
Three protein motifs have been characterized to mediate
noncovalent pADPr binding. Pleschke et al. (3) were the
ﬁrst to report a noncovalent pADPr binding motif
in DNA damage checkpoint proteins. This characteristic
pADPr binding motif, composed of interspersed basic and
hydrophobic amino acid residues, suggested for the ﬁrst
time that pADPr can act as a mediator of protein–protein
interactions. A second pADPr binding motif has been
shown by Karras and colleagues (4) to reside within
macro domains in the form of a conserved ligand binding
pocket (5). The pADPr binding of macro domain-contain-
ing proteins is particularly interesting given that this
module is mostly found in helicase proteins associated with
DNA and/or RNA unwinding activity, an important func-
tion in DNA replication, DNA repair and DNA recombi-
nation processes. A recent study from Ahel and colleagues
(6) has revealed a third structure (zinc-ﬁnger PBZ) found
in DNA repair and checkpoint proteins, which also med-
iates speciﬁc pADPr binding.
These noncovalent pADPr motifs can be the object of
pADPr-aﬃnity evaluation. Indeed, Fahrer and colleagues
(7) have published a quantitative method to assess the
binding aﬃnity of noncovalent pADPr binding proteins.
They reported remarkably high noncovalent aﬃnity to
pADPr, this aﬃnity being correlated to pADPr chain
length, in consistency with the length-dependent behavior
of pADPr in cell death (8), and the nanomolar aﬃnity of
macro domains.
Although some proteins bind pADPr through either
a covalent or noncovalent bond, some proteins closely
associated to PARPs may actually be modiﬁed by both
mechanisms. Evidence is mounting that pADPr’s func-
tions extend far beyond that of a covalent posttransla-
tional modiﬁcation. pADPr can indeed be viewed as an
eﬀector molecule that modulate the properties of its accep-
tor proteins.
In view of the scarcity of information presently
available and the potentially large number of pADPr-
associated proteins, we conducted a proteome-wide inves-
tigation to identify candidates for pADPr binding and to
determine if diversity exists in the roles of pADPr in cell
function. First, in silico identiﬁcation of consensus pADPr
binding motifs was used to systematically identify putative
pADPr binding proteins amongst a nonredundant human
protein database. Second, synthetic peptides derived from
the sequences of selected proteins that contained motifs
with high homology to the predicted pADPr consensus
binding site were tested for in vitro binding to pADPr.
Positive binding sequences were aligned to reﬁne the con-
sensus pADPr binding motif into a more stringent pattern
for increased conﬁdence in pADPr binding predictions.
Finally, in silico predictions were supported by protein–
pADPr aﬃnity assays coupled with large-scale mass spec-
trometry (MS)-based proteome analysis. Polymer blot
analysis of two-dimensionally separated HeLa cell extracts
revealed several proteins that were predicted to bind
pADPr as well as pADPr-associated proteins identiﬁed
by liquid-chromatography tandem MS (LC-MS/MS)
that were immunoprecipitated from cell cultures exposed
to extensive alkylation-induced DNA damage. Identi-
ﬁed protein candidates were classiﬁed according to bio-
logical functions and their known interactions with
pathways-related proteins so as to organize them into
biologically meaningful clusters. Collectively, our results
provide novel insights into the pADPr interactome and
generate, for the ﬁrst time, a large-scale MS-based proteo-
mic resource for identifying pADPr binding candidates.
MATERIALS AND METHODS
In silico prediction of pADPrbinding proteins
Putative pADPr binding proteins were ﬁrst screened on the
basis of the original consensus pADPr binding motif
proposed by Pleschke et al. (3). The following original
pattern value [AVILMFYW]1-X2-[KR]3-X4-[AVILMFY
W]5-[AVILMFYW]6-[KR]7-[KR]8-[AVILMFYW]9-[AVI
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Figure 1. Current experimental strategies for the identiﬁcation of
pADPr-associated proteins. Six types of experimental approaches
have been used to date to identify poly(ADP-ribosyl)ated and pADPr
binding proteins (pADPr-associated proteins). As illustrated clockwise
starting from the top: (i) identiﬁcation of in vitro and in vivo poly(ADP-
ribosyl) transferase activity of PARP-1 onto acceptor proteins (covalent
modiﬁcations) using immunological or radioactivity-based detection
methods; (ii) identiﬁcation of noncovalent pADPr binding regions
within protein amino acid sequences based on similarity with a con-
sensus pADPr binding motif; (iii) aﬃnity-based assays for the identiﬁ-
cation, validation and quantitative evaluation of noncovalent pADPr
binding [surface plasmon resonance (SPR), electrophoretic mobility
shift assays (EMSA), peptide and protein polymer blot analysis,
mono- and bidimensional gel electrophoresis coupled with polymer
blot analysis followed by MS]; (iv) in vivo evaluation of recruitment
and accumulation of pADPr binding proteins using micro irradiation-
induced DNA damage assays in live cell experiments; (v) immunopre-
cipitation assays using speciﬁc anti-pADPr antibodies to pull-down
pADPr-associated proteins; and (vi) the characterization of PARP-
associated protein domains as functional noncovalent pADPr binding
modules (e.g. the Macro domain A1pp or the zinc-ﬁnger domain PBZ).
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entries of the Swiss-Prot database (20 070 human entries
out of 392667, as indexed on 23 July 2008) using the
PattInProt search engine located on the NPS@ server
(Network Protein Sequence @nalysis, http://npsa-pbil.
ibcp.fr/) (9). A similarity level cut-oﬀ of 90% was applied.
The reﬁned pADPr binding motif [HKR]1-X2-X3-
[AIQVY]4-[KR]5-[KR]6-[AILV]7-[FILPV]8 was screened
using the same database but without mismatch (100%
similarity).
Cell culture, siRNA transfections and induction
of DNA damage
Human neuroblastoma SK-N-SH and HeLa cervical
carcinoma cell lines were cultured (air/CO2, 19:1, 378C)
in DMEM medium supplemented with 10% fetal
bovine serum (Hyclone-ThermoFisher Scientiﬁc, Ottawa,
Canada). Penicillin (100U/ml) and streptomycin (100mg/
ml) (Wisent, St-Bruno, Canada) were added to culture
media. When growth of SK-N-SH cells reached  50%
conﬂuency, cells were transfected with 5nM PARG
siRNA [hPARG: AAGAUGAGAAUGGUGAGCGAA
dTdT and hPARG control siRNA (mismatch): AAGA
UGAGAAUCCUGAGCGAAdTdT] using HiPerfect
reagent (Qiagen, Mississauga, Canada). Silencing was con-
ducted over 6 days, passaging cells every 48h to achieve
maximum PARG knockdown. Alkylating DNA damage
was performed using 100mM N-methyl-N0-nitro-N-nitro-
soguanidine (MNNG) for 5min.
Two-dimensional polymer blot analysis
Five hundred micrograms of total HeLa cell protein
extracts were subjected to high-resolution two-dimensional
electrophoresis essentially following the method devel-
oped by O’Farrell (10). Brieﬂy, cells were lyzed in a lysis
buﬀer containing 9M urea, 2% NP-40 and 2% ampho-
lines (1.6% pH 3–10 and 0.4% pH 5–7). The ﬁrst dimen-
sion (isoelectric focusing) was performed on 3 125mm
tubes using the Model 225 tube gel casting stand and
tube gel adapter (Bio-Rad, Mississauga, Canada) for
the Protean II xi cell (Bio-Rad), during which proteins
are separated according to their isoelectric points. The
second dimension (SDS–PAGE) was performed using
20 20cm gels with the Protean II xi cell. Two identical
gels were prepared: one gel was silver stained (Vorum pro-
tocol) according to Mortz et al. (11) to visualize the separa-
tion pattern. The second gel was transferred onto 0.45 mm
PVDF membrane. Polymer blot analysis and identiﬁca-
tion of pADPr binding proteins by MALDI-TOF MS
was performed as described (12).
Peptide polymer blot analysis
Peptides corresponding to the predicted pADPr binding
domain of selected proteins found by in silico analysis
were synthesized using Fmoc solid-phase peptide synthesis
with an Applied Biosystems 433A peptide synthesizer
(Supplementary Table S4). The quality of peptide synth-
esis was controlled by MALDI-TOF MS analysis and the
purity of peptide was evaluated using analytical HPLC.
Peptides were dissolved in TBS-T (10mM Tris–HCl
pH 8.0, 150mM NaCl, 0.1% Tween-20). One microgram
of each peptide was spotted onto a 21mm 50mm nitro-
cellulose ﬁlm-slide (Grace Bio-Labs, Bend, OR, USA),
air-dried, rinsed three times with TBS-T and incubated
for 1h at room temperature with gentle agitation in
TBS-T containing 250nM
32P-labeled pADPr synthesized
as described (12). It was then washed with TBS-T buﬀer
until no radioactivity could be detected in the washes. The
membrane was subsequently air-dried and subjected to
autoradiography on an Instant Imager (Perkin Elmer,
Woodbridge, Canada), which analyzes and quantiﬁes the
distribution of radioactivity on ﬂat samples.
pADPrimmunoprecipitation
SK-N-SH cells were seeded onto three 150mm cell-culture
dishes and grown up to 80–90% conﬂuency. Cells were
incubated with freshly prepared 100mM MNNG for
5min before extraction. All further steps were performed
on ice or at 48C. Two PBS washes were carried out
prior to the extraction with 2ml/plates of lysis buﬀer
[20mM Tris–HCl pH 7.5, 150mM NaCl, 0.5% NP-40,
Complete
TM protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN, USA)]. Cell lysates were
pooled, adjusted to 2M NaCl and placed on ice for
15–20min. After 30s of gentle mixing, the cell extract was
extensively dialyzed against ice-cold lysis buﬀer. Immu-
noprecipitation experiments were performed using Dyna-
beads
TM magnetic beads covalently coupled with Protein
G (Invitrogen, Burlington, Canada). The Dynabeads
TM
were washed two times with 1ml of 0.1M sodium acetate
buﬀer, pH 5.0, coated with 10–15mg of mouse monoclonal
anti-pADPr antibody clone 10H (Tulip Biolabs, West
Point, PA, USA) or equivalent amount of normal mouse
IgGs (Calbiochem-EMD Biosciences, San Diego, CA,
USA). The antibody-coupled Dynabeads
TM were incu-
bated for 1h at room temperature with 1ml of PBS
containing 1% (w/v) BSA (Sigma-Aldrich, Oakville,
Canada) to block nonspeciﬁc antibody binding sites. The
beads were ﬁnally washed three times with 1ml of lysis
buﬀerandaddedtothepADPr-proteinextractfor2hincu-
bation with gentle agitation. Samples were washed three
times with two volumes of lysis buﬀer for 5min. Protein
complexes were eluted using 150mlo f3   Laemmli sample
buﬀer containing 5% b-mercaptoethanol and boiled for
5min in a water bath. Proteins were resolved using
4–12% Criterion
TM XT Bis–Tris gradient gel (Bio-Rad)
and stained with Sypro Ruby (Bio-Rad) according to the
manufacturer’s instructions. Images were acquired using
a CCD-based Chemi-Imager 4000 imaging system and
AlphaEase software 3.3 (Alpha Innotech Corporation,
San Leandro, CA, USA).
PARG activity assays
32P-labeled automodiﬁed PARP-1 was synthesized essen-
tially as described by Me ´ nard and Poirier (13) in a
total reaction volume of 900ml containing 100mM
Tris–HCl, pH 8.0, 10mM MgCl2, 8mM dithiothreitol,
10% (v/v) glycerol, 23mg of calf thymus-activated DNA
(Sigma-Aldrich), 1mM NAD and 75mCi of
32P-labeled
NAD (GE Healthcare, Baie d’Urfe ´ e, Canada). Ethanol
Nucleic Acids Research, 2008, Vol. 36, No. 22 6961was added to this preparation dropwise to 10% (v/v) ﬁnal
concentration, with constant mixing, and the reaction
mixture was incubated for 3min at 308C. The reaction
was started by adding 20U of PARP-1 puriﬁed up to
the DNA-cellulose step as described by Zahradka and
Ebisuzaki (14). After 30min at 308C, during which time
the enzyme was modiﬁed by covalent linkage of pADPr
chains to its automodiﬁcation domain, 100mlo f3 M
sodium acetate, pH 5.2 and 700ml of propan-2-ol were
added as described by Brochu et al. (15). The reaction
mixture was kept on ice for 30min and then centrifuged
at 10 000g for 10min at 48C. The pellet was washed twice
with ice-cold 80% (v/v) ethanol, resuspended and incu-
bated at 608C for 2h in 1ml containing 1M KOH and
50mM EDTA to release the pADPr from automodiﬁed
PARP-1 by alkali digestion. Protein-free pADPr was pur-
iﬁed on dihydroxyboronyl Bio-Rex (DHBB) aﬃnity resin
as described in Shah et al. (16). PARG activity was mea-
sured by analyzing the production of ADP-ribose mono-
mers from in vitro synthesized protein-free pADPr. PARG
extracts used for immunoprecipitation experiments were
incubated with 10mM
32P-labeled pADPr for 20min at
308C. Aliquots were then spotted on PEI-F (polyethyle-
neimine F) cellulose thin layer chromatography (TLC)
sheets (Macherey-Nagel, Bethlehem, PA, USA) and devel-
oped in 0.3M LiCl and 0.9M ethanoic (acetic) acid
according to Me ´ nard and Poirier (13).
Immunoblotting
Protein extracts eluted from Dynabeads
TM were separated
on SDS–PAGE and then transferred onto 0.2mm nitrocel-
lulose membrane (Bio-Rad). After incubating 1h with
blocking solution (PBS-T containing 5% nonfat milk),
the membrane was probed overnight at room tempera-
ture with shaking, by primary antibodies to PARP-1
[clone C2-10 (1:5000)], pADPr [10H (1:2500) Tulip
Biolabs, 96-10 (1:5000)], IQGAP1 [(1:1000) Cell Signal-
ing], Apoptosis-inducing factor (AIF) [(1:5000) Sigma],
Ku80 [(1:5000) Oncogene Research Products, San Diego,
CA, USA], DNA-PK [(1:5000) Calbiochem], Adaptins
a/b/g [(1:1000/1:5000/1:5000) BD Biosciences, Missis-
sauga, Canada]. After washing with PBS-T, species-
speciﬁc horseradish peroxidase-conjugated secondary
antibody was added for 1h at room temperature. Signals
were detected with Western Lightning
TM Chemilumines-
cence reagent plus kit (Perkin Elmer).
LC-MS/MS analysis
SDS–PAGE protein lanes corresponding to control
and anti-pADPr immunoprecipitated extracts were cut
into 33 gel slices per lane using a disposable lane picker
(The Gel Company, CA, USA). Gel slices were deposited
into96-wellplates.In-gelproteindigestwasperformedona
MassPrep
TM liquid handling station (Waters, Mississauga,
Canada) according to the manufacturer’s speciﬁcations
and using sequencing-grade modiﬁed trypsin (Promega,
Madison, WI, USA). Peptide extracts were dried out
using a SpeedVac
TM.
Peptide extracts were separated by online reversed-
phase (RP) nanoscale capillary LC (nanoLC) and
analyzed by electrospray MS (ES MS/MS). The experi-
ments were performed on a Thermo Surveyor MS pump
connected to a LTQ linear ion trap mass spectrometer
(Thermo Electron, San Jose, CA, USA) equipped with a
nanoelectrospray ion source (Thermo Electron, San Jose,
CA, USA). Peptide separation took place within a
PicoFrit column BioBasic C18, 10cm 0.075mm internal
diameter (New Objective, Woburn, MA, USA) with a
linear gradient from 2% to 50% solvent B (acetonitrile,
0.1% formic acid) in 30min, at 200 nl/min. Mass spectra
were acquired using data-dependent acquisition mode
(Xcalibure software, version 2.0). Each full-scan mass
spectrum (400–2000m/z) was followed by collision-
induced dissociation of the seven most intense ions.
The dynamic exclusion function was enabled (30s exclu-
sion), and the relative collisional fragmentation energy
was set to 35%.
Interpretation oftandem MSspectra
All MS/MS samples were analyzed using Mascot (Matrix
Science, London, UK; version 2.2.0). Mascot was set up to
search against human Uniref_100 protein database assum-
ing a digestion with trypsin. Fragment and parent ion
mass tolerance were, respectively, of 0.5 Da and 2.0 Da.
Iodoacetamide derivative of cysteine was speciﬁed as a
ﬁxed modiﬁcation. Deamidation of asparagines and glu-
tamine, acetylation of lysine and arginine and oxidation
of methionine were speciﬁed as variable modiﬁcations.
Two missed cleavages were allowed.
Criteria forproteinidentification
Scaﬀold (version 01_07_00; Proteome Software Inc.,
Portland, OR, USA) was used to validate MS/MS-based
peptide and protein identiﬁcations. Peptide identiﬁcations
were accepted if they could be established at >80.0%
probability as speciﬁed by the Peptide Prophet algorithm
(17). Protein identiﬁcations were accepted if they could be
established at >90.0% probability and contained at least
two identiﬁed peptides. Protein probabilities were assigned
by the Protein Prophet algorithm (18). Proteins that con-
tained similar peptides and could not be diﬀerentiated
based on MS/MS analysis alone were grouped to satisfy
the principles of parsimony. Using these stringent identi-
ﬁcation parameters, the rate of false positive identiﬁca-
tions is <1%.
Modeling ofpADPr-associated protein networks
A graphical representation of the functional connections
between pADPr-associated proteins was ﬁrst computed
using ﬁltered Bibliosphere (Genomatix Software, Ann
Arbor, MI, USA) interaction maps (co-citation functional
level B2). Bibliosphere outputs a bibliometric-based clus-
tering of related genes. Searching for biological processes
enrichment of the pADPr binding network against the
whole Gene Ontology (GO) hierarchy was performed
using BiNGO v2.0 [19] and visualized with Cytoscape
v2.5 [20]. GO annotation’s P-values were obtained by
hypergeometric statistical testing (cluster versus the
whole-annotation bank) and corrected using the
Benjamin and Hochberg false discovery rate included in
6962 Nucleic Acids Research, 2008, Vol. 36, No. 22the BiNGO software. GO database was downloaded
on 1 July 2007. GoMiner [21] was used to reveal protein
distributions within selected GO categories. For both
in silico analysis, gene identiﬁcation codes were converted
or retrieved using the protein’s Swiss-Prot accession
numbers.
Evaluation of proteindomain and family distribution
The Pfam (http://pfam.sanger.ac.uk/) domains were
obtained by parsing the ‘swisspfam’ (version Pfam 22.0,
July 2007, 9318 families) database using in-house Ruby
scripts (version 1.8.6) which output Microsoft Excel-
compatible spreadsheets suitable for further analysis.
Datasets were generated from the both the original and
reﬁned pADPr binding motifs, and the protein dataset
that contains all the proteins identiﬁed by LC-MS/MS
from pADPr immunoprecipitation experiments.
RESULTS
InsilicoidentificationofnoncovalentpADPrbindingproteins
There are currently three protein modules known to bind
pADPr. However, they diﬀer greatly in their abundance
within the human proteome. The macro domain that has
been demonstrated to bind pADPr (4,5) (A1pp) could
only be found in 27 human proteins using the InterPRO
(22) protein database. Human proteins with the conserved
zinc-ﬁnger motif PBZ are even rarer, since there are only
four human proteins reported to match this stringent
motif. On the other hand, 862 human putative pADPr
binding proteins were extracted from the Swiss-Prot data-
base following a similarity search based on the noncoval-
ent pADPr binding motif deﬁned by Pleschke et al. (3)
found within DNA damage checkpoint proteins (Supple-
mentary Table S1). This pADPr binding sequence is based
on the consensus motif hxbxhhbbhhb (where h stands for
hydrophobic residues, b for basic residues and x for any
amino acid residues). However, the level of conservation
of the proposed pADPr binding motif is low but still char-
acterized by preferred amino acid residues and some more
variable positions. This is a rather broad pADPr binding
signature that can be found in a much larger diversity of
proteins than the macro domain and zinc-ﬁnger motifs.
Consequently, we searched for human proteins with a
high similarity level but without any strict requirement
for speciﬁc amino acids at a given position within the
pADPr binding sequence, except for the two positively
charged lysine or arginine residues in the center of the
motif which seem to be the less tolerant positions. Follow-
ing these criteria, we screened the Swiss-Prot protein
library using the PattInProt search engine (9) with a simi-
larity level threshold of 90% which allows the detection
of degenerated sequences. The resulting dataset of more
than 800 proteins (Supplementary Table S1) represents
an impressive number of proteins. Although it probably
displays a high rate of false positives, this in silico screen-
ing test is considered valuable because it greatly increase
the likelihood of detecting a pADPr binding protein.
Refinement ofthe original pADPrbinding motif
We ﬁrst wanted to increase the number of experimentally
validated pADPr binding sites so as to better deﬁne a
consensus pADPr binding pattern and get a more repre-
sentative view of the amino acid frequency at any given
position. To achieve this goal, we selected some putative
pADPr binding proteins suspected to be involved in
pADPr-associated biological processes and synthesized
peptides that corresponded to the region most similar to
the consensus pattern. Table 1 presents the comprehensive
list of pADPr binding regions that have been tested using
synthetic peptides in polymer blot assays. For the present
study, 24 new peptides were synthesized and assayed for
pADPr binding. The hnRNP A1 peptide was used as a
positive control since it has been validated as a strong and
speciﬁc pADPr binding peptide (12). About one-third of
the new peptides (9 out of 24) were characterized as
pADPr binding peptides (Figure 2A). Most of the vali-
dated pADPr binding peptides share a restricted set of
amino acids at speciﬁed positions of the pADPr bind-
ing consensus sequence (Figure 2B) from which we can
derive a reﬁned consensus motif. This modiﬁed consensus
sequence with a much more limited set of amino acids
at conserved positions, [HKR]1-X2-X3-[AIQVY]4-[KR]5-
[KR]6-[AILV]7-[FILPV]8, represents a more stringent
version of the original consensus sequence proposed by
Pleschke and collaborators (3). In contrast to the more
relaxed consensus, the two positively charged amino
acids residues [KR]5-[KR]6 are strictly followed by either
A, I, L or V ([AILV]7) which are classiﬁed as residues with
alkyl side chains. These strong pADPr binding regions
do not require a conserved hydrophobic residue at posi-
tion 3, but the positively charged amino acid residues at
position 1 is conserved. This reﬁned pattern of validated
pADPr binding sites is conserved in histone H4 (23,24)
and hnRNP A1, whose pADPr binding motifs have
been validated experimentally as strong binding sites (12).
The reﬁned pattern was searched without mismatch
tolerance against the Swiss-Prot database to extract a
sub-dataset of pADPr binding proteins with high simi-
larity to the pADPr binding sites that were validated in
our study (Supplementary Table S2). Interestingly, the
526 unique proteins in this dataset are much better con-
nected to DNA and chromatin functions than the original
dataset. Unique proteins to the dataset generated with
the reﬁned pADPr binding motif include: DNA excision
repair proteins ERCC-2 and ERCC-6, DNA polymer-
ase subunit alpha B, DNA primase small subunit, DNA
replication licensing factors MCM3, MCM5, MCM7,
DNA topoisomerase 2-beta, mitochondrial DNA topo-
isomerase I, SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A member
5 (SMCA5), Centromere protein T (CENP-T), the DNA
damage checkpoint response protein HUS 1, several his-
tone metabolism-associated proteins, such as the histone
acetyltransferases MYST3, MYST4, histone acetyltrans-
ferases p300 (25) and PCAF (26), or the newly identiﬁed
pADPr binding protein DEK (27). Because several
of these proteins are closely related to known pADPr-
modulated pathways, the reﬁned consensus appears to
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Swiss-Prot accession Protein description Sites pADPr binding motif Binding Reference
Synthetic peptides assayed in this study (see Figure 2A)
Q9NWT8 Aurora-A kinase interacting protein 132–153 KIRRRKMNHHKYRKLVKKTRFL + This study
Q96GD4 Serine/threonine-protein kinase Aurora-B 182–203 EELADALMYCHGKKVIHRDIKP   This study
P55957 BH3-interacting domain death agonist [BID] 145–166 EKTMLVLALLLAKKVASHTPSL + This study
P38398 Breast cancer type 1 susceptibility protein
[BRCA]
123–144 SIIQSMGYRNRAKRLLQSEPEN   This study
Q9BXL7 Caspase recruitment domain protein 11
[CAR-11]
740–761 VTLHYKVNHEGYRKLVKDMEDG   This study
P49450 Centromere protein A [CENP-A] 51–72 IRKLQKSTHLLIRKLPFSRLAR + This study
Q12798 Centrin-1 58–79 RALGFEPRKEEMKKMISEVDRE   This study
Q13616 Cullin-1 460–481 DVFQKFYAKMLAKRLVHQNSAS   This study
Q03468 DNA excision repair protein ERCC-6 284–297 ERKKGGCNKRAARKAPAPVTPP + This study
Q5VTC7 Hexokinase domain-containing protein 1 420–441 HPQYPKRLHKVVRKLVPSCDVR + This study
A4QPB0 IQ motif containing GTPase activating
protein 1 [IQGAP1]
1413–1435 SEQEAEHQRAMQRRAIRDAKTP   This study
Q76GR4 DNA ligase 1 46–67 VSESDSPVKRPGRKAARVLGSE   This study
P43246 DNA mismatch repair protein MSH2 806–827 TTEETLTMLYQVKKGVCDQSFG   This study
P19367 Hexokinase-1 420–441 HPQYSRRFHKTLRRLVPDSDVR   This study
Q14764 Major vault protein MVP 499–520 SLSAGRPKRPHARRALCLLLGP + This study
Q15172 Serine/threonine-protein phosphatase 2A
56kDa regulatory subunit alpha isoform
18–39 SEKVDGFTRKSVRKAQRQKRSQ   This study
O60264 SWI/SNF-related matrix-associated actin-
dependent regul. of chromatin A5 [SMCA5]
906–927 RGEARIQRRISIKKALDTKIGR   This study
P11387 DNA topoisomerase 1 263–284 MLDHEYTTKEIFRKNFFKDWRK   This study
P11387 DNA topoisomerase 1 533–554 DSIRYYNKVPVEKRVFKNLQLF   This study
P11387 DNA topoisomerase 1 669–690 KADAKVMKDAKTKKVVESKKKA   This study
Q02880 DNA topoisomerase 2-beta 736–757 IPSLVDGFKPGQRKVLFTCFKR + This study
O43684 Mitotic checkpoint protein BUB3 145–166 VSGDRLIVGTAGRRVLVWDLRN + This study
P24941 Cell division protein kinase 2 [CDK2] 76–97 LYLVFEFLHQDLKKFMDASALT   This study
Q15021 Condensin complex subunit 1 518–539 GRIYQLLAKASYKKAIILTREA  + This study
P09651 Heterogeneous nuclear ribonucleoprotein A1
[hnRNP A1]
93–114 EDSQRPGAHLTVKKIFVGGIKE  + This study + (12)
Peptides assayed in other studies
P22626 Heterogeneous nuclear ribonucleoprotein
A2/B1
100–121 EESGKPGAHVTVKKLFVGGIKE  + (12)
P10155 60kDa SS-A/Ro ribonucleoprotein 138–158 SMKCGMWGR-ALRKAIADWYNE  + (12)
P62805 Histone H4 24–45 RDNIQGITKPAIRRLARRGGVK  + (12)
P49959 Double-strand break repair protein MRE11 564–585 AATNKGRGRGRGRRGGRGQNSA  + (45)
Q13315 Serine-protein kinase ATM 98–119 SSLVKYFIKCANRRAPRLKCQE  + (46)
Q13315 Serine-protein kinase ATM 2734–2755 MCNTLLQRNTETRKRKLTICTY  + (46)
P29966 Myristoylated alanine-rich C-kinase
substrate [MARCKS]
149–170 ETPKKKKKRFSFKKSFKLSGFS  + (3)
P52701 DNA mismatch repair protein MSH6 299–319 KRKRMVTGNGSLKRKKSSRKET  + (3)
P38936 Cyclin-dependent kinase inhibitor 1 [p21] 143–164 QTSMTDFYH-SKRRLIFSKRKP + (3)
P23025 DNA repair protein complementing XP-A
cells [XPA]
205–226 EVRQENREKMKQKKFDKKVKEL  + (3)
P18887 DNA repair protein XRCC1 382–403 RKEWVLDCHRMRRRLPSRRYLM  + (3)
P49916 DNA ligase III 18–39 KKCKEKIVK-GVCRIGKVVPNP  + (3)
Q07864 DNA polymerase epsilon catalytic subunit A 720–741 KRRLADYCRKAYKKIHITKVEE  + (3)
P12956 DNA repair protein XRCC6 [Ku70] 232–253 HFEESSKLEDLLRKVRAKETRK  + (3)
P78527 DNA-dependent protein kinase catalytic
subunit [DNA-PK]
2733–2754 MRDQEKLSLMYARKGVAEQKRE  + (3)
Q00653 Nuclear factor NF-kappa-B p100 subunit 170–191 QRELEQEAK-ELKKVMDLSIVR  + (3)
P35228 Nitric oxide synthase, inducible [NOS2] 498–519 THVWQDEKRRPKRREIPLKVLV  + (3)
O76075 DNA fragmentation factor subunit beta
[CAD]
144–165 GLESRFQSKSGYLRYSCESRIR  + (3)
O14746 Telomerase reverse transcriptase 960–981 FNRGFKAGRNMRRKLFGVLRLK  + (3)
P43246 DNA mismatch repair protein MSH2 230–251 ADFSTKDIYQDLNRLLKGKKGE    (3)
P38936 Cyclin-dependent kinase inhibitor 1 [p21] 8–28 VRQNPCGSK-ACRRLFGPVDSE    (3)
P23025 DNA repair protein complementing XP-A
cells [XPA]
22–42 ASVRASIER-KRQRALMLRQAR    (3)
P13010 DNA repair protein XRCC5 [Ku86] 17–138 VIQHETIGKKFEKRHIEIFTDL    (3)
P49916 DNA ligase III 779–800 SRKAPSKPSASTKKAEGKLSNS    (3)
Q6DRD3 DNA polymerase beta 22–42 ANYERNVNR-AIHKYNAYRKAA    (3)
Q6DRD3 DNA polymerase beta 34–55 KYNAYRKAASVIAKYPQKIKSG    (3)
The alignment includes known and putative pADPr binding proteins based on the pADPr binding motif (hxbxhhbbhhb)(3). The central amino acid
couple K/R is shown on a black background. Proximal residues that ﬁt the consensus are indicated under a gray background. Swiss-Prot accession
codes, sites mapping and experimental pADPr binding validation are indicated for each peptide.
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terpart. This reﬁned motif lowers the screening eﬀort to a
more manageable level and should be considered as a ﬁrst
step in an attempt to identify pADPr binding proteins.
Identification ofnoncovalent pADPr binding proteins
by polymer blot analysis following two-dimensional
electrophoresis
As in silico predictions are still limited in their ability
to identify all pADPr binding proteins, it mostly serves
a rapid approach to identify putative pADPr binding
targets. Until they are more accurate, in silico-identiﬁed
pADPr binding proteins will need to be validated experi-
mentally. Thanks to the development of high-throughput
proteomics technologies, proteome-wide identiﬁcation
of pADPr binding proteins is now manageable. Half a
milligram of HeLa cell protein extract was resolved into
discrete spots by two-dimensional electrophoresis and
transferred onto PVDF membrane. pADPr binding
proteins were identiﬁed by matrix-assisted laser deso-
rption ionization (MALDI) MS after incubation with
32P-labeled pADPr and autoradiography (Figure 3). We
selected tube-gel two-dimensional electrophoresis instead
of the more recent immobilized pH gradient (IPG) two-
dimensional isoelectric focusing (IEF) because of the
increased sample loading capacity and because reproduci-
bility was not as important as it would have been in a
diﬀerential proteome analysis. Most of the pADPr bind-
ing proteins are found at high pH values (positively
charged) as we would expect for proteins involved in
DNA/RNA transactions or speciﬁcally involved in the
binding of a negatively charged polyanion, such as
pADPr. Known pADPr binding proteins, such as
hnRNPs (12) still represent many of the abundant
pADPr binding proteins identiﬁed by this method
(Table 2). DNA-binding proteins, such as members of
the zinc-ﬁnger protein family, are also found in several
spots. In addition, the presence of the major vault protein
(MVP) is interesting since its pADPr binding region,
Figure 2. Polymer blot analysis. (A) Synthetic peptides corresponding to putative pADPr binding proteins as revealed by in silico prediction based
on the consensus sequence proposed by Pleschke et al. (3) were dot-blotted onto nitrocellulose-coated glass slides, screened with
32P-pADPr
and autoradiographied (see Supplementary Table S1 for the complete list of predictions). Amino acid sequences used for peptide synthesis are
provided in Supplementary Table S4. (B) A reﬁned pADPr binding consensus is generated from the sequence alignment of validated pADPr binding
peptides. Experimentally veriﬁed pADPr binding regions from pADPr dot blot analysis were aligned to derive a reﬁned pADPr binding motif and
to computationally screen protein sequence database with the goal of achieving higher reliability and minimizing false positive identiﬁcations
(see Supplementary Table S2 for a listing of proteins that match the reﬁned pADPr binding consensus).
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tested (Figure 2A). Other proteins identiﬁed by MALDI
MS also contain a pADPr binding site that match the
reﬁned consensus motif, including DNA replication licen-
sing factor MCM5, Cullin 1 and Cullin 4A. Cell-cycle reg-
ulators CDK1 and CDK2 are also noteworthy
identiﬁcations as well as Caspase-10. The identiﬁcation
of electrophoretically transferred, two-dimensionally sepa-
rated proteins by MS suﬀers important limitations since
high molecular weight proteins are particularly diﬃcult
to analyze this way and multiple co-migrating proteins in
single spot can lead to ambiguous identiﬁcations.
Immunoprecipitation ofpADPr-associated proteins
following alkylation-induced DNA damage
The large-scale validation and identiﬁcation of pADPr
binding proteins mostly relied on polymer blot analysis
projects based on one- or two-dimensional electrophore-
sis, both techniques requiring heavy denaturation steps
for protein separation. An alternative approach to explore
the nature of the interaction between cellular proteins and
pADPr under more physiological conditions and with
increased dynamic range is to use speciﬁc anti-pADPr
antibodies to immunoprecipitate pADPr-associated pro-
teins and pADPr-containing protein complexes. However,
even if pADPr synthesis can be achieved by several
PARPs, basal levels of pADPr in unstimulated cells
are extremely low and probably insuﬃcient to allow the
identiﬁcation of pADPr binding proteins in the absence of
PARP-1 activation. Therefore, we used genotoxic stress to
trigger activation of PARPs and thereby increase pADPr
levels by 10- to 500-fold (2), up to concentrations appro-
priate for aﬃnity puriﬁcation. Nonetheless, because of
the transient nature of pADPr following PARPs activa-
tion in response to DNA strand breaks, we needed a
model in which pADPr levels would be sustained. More-
over, we needed a protein extraction procedure that would
extract nuclear matrix-associated proteins since this struc-
ture represents a major site of pADPr metabolism. Indeed,
Cardenas-Corona and colleagues (28) have shown that
most of the pADPr is associated with the nuclear matrix
and possibly tightly embedded within it since DNAse
treatments are ineﬃcient to release pADPr. In order to
circumvent these two diﬃculties, pADPr hydrolysis was
ﬁrst signiﬁcantly reduced by knocking down endogenous
PARG in SK-N-SH cells, one of the most extensively
studied neuroblastoma cell line used as a model for cyto-
toxicity, radiobiology and DNA damage response. With
respect to the second concern, we performed high salt
protein extractions, a procedure that has shown optimal
results for the release of chromatin-bound pADPr.
Extracts dialyzed against a nondenaturing immunopreci-
pitation buﬀer were used to pull-down pADPr and
pADPr-associated proteins.
Figure 4A and B show that impaired pADPr turnover
in PARG siRNA-treated cells results in sustained levels
of pADPr. In contrast, pADPr levels in untreated cells do
not increase as much and start decreasing after 10min.
Long-term PARG siRNA treatment (6 days) was neces-
sary to reduce endogenous PARG levels by 80% as esti-
mated from TLC PARG activity assays (Figure 4C and D),
a maximum in PARG expression knockdown also
reported by Cohausz et al. (29) in a pADPr -metabolizing
enzymes study on alkylation-induced cell death. We
coupled anti-pADPr mouse monoclonal antibodies
(clone 10H) to magnetic Protein-G coated Dynabeads
to selectively pull-down pADPr-associated proteins.
Normal mouse IgGs were used as a control reagent for
immunoprecipitations using mouse monoclonal anti-
bodies. Immunoprecipitated proteins were stained using
SYPRO Ruby ﬂuorescent stain after 1D SDS–PAGE
Figure 3. Two-dimensional polymer blot analysis. HeLa cell extracts were separated by tube-gel isoelectric focusing, resolved by SDS–PAGE and
transferred onto PVDF membrane. The left panel shows the bidimensional protein separation as revealed by silver staining. The right-hand panel
shows a corresponding two-dimensional-gel transferred onto a PVDF membrane for polymer blot analysis. Incubation with
32P-pADPr followed by
autoradiography reveals a binding-protein pattern. Numbered spots were excised for identiﬁcation by peptide mass ﬁngerprinting (see Table 2 for
complete spot identiﬁcations).
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ted across a wide range of molecular weights with minimal
nonspeciﬁc binding from the control IgGs.
LC-MS/MS identification of pADPr-associated proteins
from SK-N-SH immunoprecipitates
Immunoprecipitated proteins resolved by SDS–PAGE
were manually excised from the gel and identiﬁed
using LC-MS/MS. More than 300 speciﬁc proteins
were identiﬁed with stringent protein identiﬁcation
probabilities criteria as described in Materials and meth-
ods section (Supplementary Table S3). Hallmark proteins
of the DNA damage response and repair pathways are
collectively over-represented in the pADPr-associated
protein dataset (Figure 5), with the notable identiﬁca-
tion of PARP-1, DNA-PK, XRCC5 (Ku80/86), MSH2,
MSH6 and the DNA damage-binding protein 1 (DDB1/
Xeroderma pigmentosum group E-complementing pro-
tein). There are also several important proteins involved
in DNA replication and transcription including DNA rep-
lication licensing factors MCM3/MCM4/MCM5/MCM7,
and DNA topoisomerase II beta whose corresponding
pADPr binding region showed strong interaction
with pADPr in polymer blot assays (Figure 2A).
The minichromosome maintenance (MCM) proteins are
DNA helicases involved in the maintenance of genomic
stability in pathways that encompass DNA replication
Table 2. Identiﬁcation of pADPr binding proteins by MALDI-TOF MS
Spot
number
Swiss-Prot
accession
Protein description Protein function
1 P10155 60kDa SS-A/Ro ribonucleoprotein RNA transcription
Q9Y6M9 NADH dehydrogenase 1 beta subcomplex subunit 9 Mitochondrial electron transport
O76080 AN1-type zinc-ﬁnger protein 5 May be involved in transcriptional regulation
2 P09651 Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) RNA transcription
3 P17098 Zinc-ﬁnger protein 8 May be involved in transcriptional regulation
P56202 Cathepsin W Cysteine-type peptidase activity
P23193 Transcription elongation factor A protein 1 RNA transcription
P06493 Cell-division control protein 2 homolog (CDK1) Cell-cycle progression and RNA transcription
P24941 Cell-division protein kinase 2 (CDK2) Cell-cycle progression and RNA transcription
4 P09651 Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) RNA transcription
P17038 Zinc-ﬁnger protein 43 May be involved in transcriptional regulation
5 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 RNA transcription
6 P51523 Zinc-ﬁnger protein 84 May be involved in transcriptional regulation
P17024 Zinc-ﬁnger protein 20 May be involved in transcriptional regulation
P50458 LIM/homeobox protein Lhx2 RNA transcription
O00257 E3 SUMO-protein ligase CBX4 (Polycomb 2 homolog) RNA transcription
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 RNA transcription
7 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 RNA transcription
8 Q9UK10 Zinc-ﬁnger protein 225 May be involved in transcriptional regulation
P33992 DNA replication licensing factor MCM5 DNA replication
O14628 Zinc-ﬁnger protein 195 May be involved in transcriptional regulation
P51523 Zinc-ﬁnger protein 84 May be involved in transcriptional regulation
9 No identiﬁcation
10 P04720 Elongation factor 1-alpha 1 Translational elongation
11 P06213 Insulin receptor Insulin receptor signaling pathway
P20592 Interferon-induced GTP-binding protein Mx2 GTPase activity
P11171 Protein 4.1 structural constituent of cytoskeleton
Q02928 Cytochrome P450 4A11 Fatty acid metabolic process
P31948 Stress-induced-phosphoprotein 1 Response to stress
P50458 LIM/homeobox protein Lhx2 RNA transcription
12 P31948 Stress-induced-phosphoprotein 1 Response to stress
13 Q01742 Fibroblast growth factor receptor 2 Fibroblast growth factor receptor activity
Q92851 Caspase-10 [Precursor] Induction of apoptosis
P09651 Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) RNA transcription
14 Q9NZL3 Zinc-ﬁnger protein 224 May be involved in transcriptional regulation
15 No identiﬁcation
16 No identiﬁcation
17 No identiﬁcation
18 No identiﬁcation
19 P18206 Vinculin Cell adhesion
P26232 Catenin alpha-2 Cell adhesion
Q13616 Cullin-1 G1/S transition of mitotic cell cycle
Q14764 Major vault protein Vaults structure
O14983 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Calcium ion transport
20 No identiﬁcation
21 No identiﬁcation
22 No identiﬁcation
HeLa cell extracts were separated by two-dimensional gel electrophoresis and the spots corresponding to pADPr binding proteins were revealed by
polymer blot analysis. See Figure 3 for spot references.
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duplexes (30). Other helicases, such as the RNA helicases
(DDX, DHX, DEAD/H families) are also remarkably
abundant in the pADPr-associated protein dataset.
The number of observed peptides by LC-MS/MS for a
given protein is semi-quantitative as it often reﬂects the
relative abundance of the protein in the analyzed sample.
Predominant proteins were estimated from their number
of unique peptides. Supplementary Table S3, which lists
all the proteins identiﬁed by LC-MS/MS in immuno-
precipitates, presents the proteins in order of decreasing
number of peptides. Proteins identiﬁed with high sequence
coverage like PARP-1, IQGAP1, DNA-PK or Ku80
(XRCC5) were validated by western blot (Figure 6).
In addition, Figure 6 shows that pADPr is selectively
enriched in the pull-down extracts. AIF, which had been
identiﬁed with only two unique peptides, also appeared
with high speciﬁcity in western blot, thus validating
the MS data. The presence of vesicle-associated adaptins
isoforms a, b and g in pADPr immunoprecipitates was
also validated by western blot analysis (Figure 6). Unex-
pectedly, many vesicular proteins involved in the control
of endosomal dynamics, such as the coatomer subunit
alpha (COPA) and clathrin-associated adaptor protein
AP-2, are also part of the pADPr-associated dataset. It
is however noteworthy that adaptor proteins AP-1 and
AP-2 as well as golgi-associated proteins are predicted to
be pADPr binding proteins based on in silico analysis
(Supplementary Table S2). These results provide addi-
tional support for a link between poly(ADP-ribosyl)ation
and traﬃcking of endosomal vesicles (31–33).
In silico predictions and experimental discoveries are
obviously complementary approaches for the exploration
of the pADPr interactome. The LC-MS/MS identiﬁcation
of the splicing factor ASF/SF2 (Supplementary Table S3),
a recently reported pADPr binding protein (34), in the
Figure 4. pADPr levels are increased and sustained in SK-N-SH cells treated with PARG siRNA following alkylation-induced DNA damage.
(A) Time course western blot analysis of pADPr accumulation in SK-N-SH cells following 100 mM MNNG treatment in both control and
PARG siRNA treated cells. Crude protein extracts were loaded and subjected to SDS–PAGE and immunoblotting. Blots were revealed with
anti-pADPr polyclonal antibody 96-10 as described in Materials and methods section. (B) Western blot quantiﬁcation of pADPr levels from control
(full line) and PARG siRNA-treated cells (dashed line) following 100 mM MNNG treatment. (C) Evaluation of PARG knockdown using PARG
TLC activity assays. Silencing was conducted over 6 days, passaging cells every 48h to achieve maximum PARG knockdown. Whole-cell extracts
were prepared from cultured cells that had been treated with either control or PARG siRNA. PARG activities were detected by TLC analysis
of reaction mixtures containing these cell extracts and
32P-labeled pADPr as a substrate. Substrate remained at the origin of the TLC plate, while
ADP-ribose products migrated towards the top of the TLC plate following development by 0.3M LiCl and 0.9M ethanoic (acetic) acid. (D) Relative
PARG residual activity in SK-N-SH cells after 6-day silencing as determined from the TLC quantiﬁcation of PARG reaction products.
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tates illustrate this complementarity since no consensus
motifs were able to predict its pADPr binding.
Modeling ofpADPr-associated protein networks
Unorganized datasets containing numerous proteins
remain hard to analyze and the possibility to draw
conclusions is hampered by the apparent complexity.
We used systems biology data mining tools to elucidate
the dynamic interplay of more than 300 putative pADPr-
associated proteins in our dataset. Based on structured
GOs annotations, we ﬁrst determined which biological
process categories were statistically over-represented in
the immunoprecipitated pADPr-associated protein data-
set. The statistical analysis was performed with a BiNGO
(19) implementation in Cytoscape (20). BiNGO is a tool
developed to highlight predominant functional themes
in a dataset and to visualize them as an integrated molec-
ular interaction network. Figure 7 shows the network
distribution of predominant GO terms associated with
pADPr-associated proteins in immunoprecipitates.
Figure 5. SDS–PAGE analysis of pADPr-associated proteins from MNNG-treated and PARG-silenced SK-N-SH cells after immunoprecipitation
with anti-pADPr antibodies. pADPr-associated proteins were immunoprecipitated using anti-pADPr mouse monoclonal antibody clone 10H bound
to Protein G coated magnetic beads. Immunoprecipitates were resolved by 4–12% SDS–PAGE and stained with SYPRO Ruby ﬂuorescent dye.
Normal mouse IgGs were used to assess nonspeciﬁc binding. Selected proteins identiﬁed by LC-MS/MS, mostly involved in DNA/RNA transactions,
are shown (see Supplementary Table S3 for complete protein listing).
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emerging from the protein population as we would expect.
Statistically signiﬁcant over-represented ontologies of
pADPr-associated proteins are grouped into six categories
that encompass the major PARP-1-dependent pathways
(chromosome organization and biogenesis, DNA repair,
DNA replication), pADPr-regulated functions (progression
through cell cycle) and mRNA metabolism/protein synthesis
for which several studies suggest a link with poly(ADP-
ribosyl)ation reactions (12,35–38).
A literature mining tool called Bibliosphere (Genomatix
Software Inc.) was also used to visualize the relations
between proteins based on the degree of interconnection
for their corresponding genes (Supplementary Figure S1).
In the Bibliosphere generated network, related genes are
clustered around ‘hubs’ that play central role in the bio-
logical pathways. In this representation, PARP-1 is dis-
played as the central molecule linking all the pathways.
The functional categories revealed by the Bibliosphere
network are similar to the results obtained with the GO
classiﬁcation tool. Biological processes, such as struc-
tural organization and function of the nucleus and chro-
matin, cellular response to DNA double-strand breaks,
DNA mismatch repair, DNA replication and genome
integrity, apoptosis and mRNA metabolism/protein syn-
thesis are predominant and strongly support the
Figure 7. Graphical network representation of pADPr-associated proteins identiﬁed by LC-MS/MS in anti-pADPr immunoprecipitates. Functional
categorization of pADPr-associated proteins was performed using GO annotations. Over-represented categories were statistically identiﬁed using
BiNGO and visualized with Cytoscape. The size of the terms (circles) is representative of the proportional protein abundance in the dataset and the
color shading indicates the degree of statistical signiﬁcance (darker shades indicate stronger signiﬁcance).
Figure 6. Validation of selected pADPr-associated proteins identiﬁed by LC-MS/MS using western blot analysis of pADPr immunoprecipitates. The
speciﬁcity of the pADPr immunoprecipitation using anti-pADPr 10H monoclonal antibodies was evaluated by immunoblot analysis as described in
Materials and methods section. The same proteins were not precipitated by normal mouse IgGs, conﬁrming the speciﬁcity of the pull-down.
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tion graph (Figure 7). BiNGO and Bibliosphere are two
independent tools for data integration and visualization
that provided converging results. However, they can com-
plement each other and deliver a more global view of the
pADPr-associated biological network.
Comparative distribution of pADPrbinding candidates
in predicted and experimental datasets
An estimation of the predominant protein domains
found within the computationally predicted and
experimentally veriﬁed pADPr binding protein datasets
based on the Pfam protein families database (39) was per-
formed (Figure 8). Clearly, proteins containing the classi-
cal zinc-ﬁnger motif (zf-C2H2) are over-represented in the
in silico protein dataset obtained through searching a pat-
tern with high similarity to the original motif (Figure 8A).
However, the proteins revealed by our reﬁned motif are
enriched in additional pathways involving nucleic acids
binding (Figure 8B). While zinc-ﬁnger proteins still repre-
sent an important category, RNA recognition motifs
(RRM_1) now occur frequently as they do for the
Figure 8. Distribution of protein domains and families in computationally predicted and experimentally validated pADPr binding proteins. The
graph shows the number of occurrences for the 12 most common Pfam domains in (A) putative pADPr binding proteins identiﬁed through a 90%
similarity sequence search based on the original consensus pADPr binding motif (Supplementary Table S1), (B) a sub-dataset of putative pADPr
binding proteins corresponding to the reﬁned pADPr binding module derived from peptides polymer blot analysis (Supplementary Table S2) and (C)
pADPr-associated proteins identiﬁed by MS in anti-pADPr immunoprecipitation assays in SK-N-SH cells following alkylation-induced DNA
damage (Supplementary Table S3).
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members of the zf-C3HC4 (Ring ﬁnger) family are also
found with this more stringent motif screen. Ring-ﬁnger
proteins notably includes Rad 5/Rad 18 (40), BRCA1 (41)
and RNF8 (42,43), a group of proteins known to mediate
cooperation between ubiquitin-conjugating enzymes in
DNA repair, and CHFR, a pADPr binding ubiquitin
lyase involved in mitotic stress response (6,44). Another
protein domain speciﬁcally abundant in the dataset gen-
erated with the reﬁned pADPr binding motif is the
SNF2_N domain (Figure 8B), which is found in proteins
involved in a variety of processes including transcription
regulation, DNA repair, DNA recombination and chro-
matin unwinding. Clearly, the in silico protein dataset gen-
erated with the reﬁned pADPr binding motif is more
closely related to the experimentally generated one.
Compared with the dataset generated with the original
consensus, both the in silico reﬁned motif and the experi-
mental dataset feature a high proportion of protein motifs
related to RNA metabolism (RRM_1, Helicase_C, KH_1,
DEAD, H2A) and chromatin-remodeling proteins. That
strongly suggests that the reﬁned pADPr binding motif
dataset is representative of the actual biological diversity
of pADPr binding proteins.
From the comparative evaluation of in silico-based pre-
diction of pADPr binding proteins and pADPr-associated
proteins found in pADPr immunoprecipitates, one can
conclude that both the original and the reﬁned consensus
pADPr binding motif are appropriate for the prediction of
pADPr binding proteins since both motifs are represented
in about the same number of experimentally identiﬁed
proteins sequences. This can be seen on the Venn diagram
displaying the distribution of pADPr binding candidates
among the three approaches selected for this study
(Figure 9). At ﬁrst look, it might seem that the number
of experimentally validated proteins is low compared with
the large number of predicted pADPr binding proteins.
However, that statement should be put into context.
First, in silico analysis only considers primary amino
acid sequences; that is, although the use of a consensus
sequence for database searching does improve the likeli-
hood of detecting pADPr binding substrates, it does not
take into account the structural determinants required for
protein–pADPr interaction and hence leads to some false
positives. Second, in silico predictions are performed over
the entire human proteome without considering cell- or
tissue-speciﬁc protein expression. Third, MS is not able
to detect proteins of very low absolute or relative abun-
dance whereas large dynamic range and low protein con-
centrations do not aﬀect computer-based predictions.
Finally, proteins that are part of stable pADPr-containing
protein complexes or making strong interactions with
Figure 9. Venn diagram illustrating the overlap between the three pADPr binding candidates datasets described in this study. Overlapping circles
shows the distribution of in silico predicted proteins revealed through the use of the consensus pADPr binding motif proposed by Pleschke et al. (3)
and the reﬁned pADPr binding motif derived from sequence alignment of experimentally validated pADPr binding regions from peptide polymer
blot analysis. The relationship between the two in silico prediction approaches and experimental identiﬁcation of pADPr-associated proteins in
pADPr immunoprecipitates is illustrated as a third intercepting circle.
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not appear in predicted datasets but will likely be identi-
ﬁed using experimental approaches. More rigorous studies
will be required to improve prediction reliability for
pADPr binding proteins and reach a lower rate of false
positive identiﬁcations. Even if the protein datasets pre-
dicted by the two pADPr binding motifs both share a bias
towards nucleic acid metabolism, only 98 proteins are
common to both and their limited overlap makes them
complementary. On the other side, 43 proteins identiﬁed
Table 3. A summary of the major pADPr-regulated pathways
Biological processes pADPr binding and pADPr-associated proteins Functions References
DNA damage signaling
and DNA repair
DNA-PK, XRCC1, XRCC5 (Ku86), XRCC6 (Ku70), MSH2,
MSH6, DNA damage-binding protein 1 (Xeroderma pigmento-
sum group E-complementing protein), DNA excision repair
protein ERCC-6, BRCA1, DNA repair and recombination
protein RAD54-like, hnRNPs, Non-POU domain-containing
octamer-binding protein (54kDa nuclear RNA- and DNA-binding
protein (PSF/p54(nrb))), DNA-repair protein complementing
XP-C, alkylated DNA repair protein alkB homolog 4, XPA,
p53, Mre11, ATM, p21, DNA ligase 3, Aprataxin PNK-like
factor (APLF), DNA cross-link repair 1A protein (SMN1)
Detection and early
response to DNA
strand-breaks, DNA
repair
(3,7,45–56)
Modiﬁcation of
chromatin
structure
Condensin complex subunit 1 (hCAP-D2/Eg7), SMC2, SMC4,
Chromobox protein homolog 1/5, Lamin-A/C, SWI/SNF-
related matrix-associated actin-dependent regulator of chromatin
subfamily A member 5, Histones, Chromodomain-helicase-
DNA-binding protein 1/5
Compaction and
decondensation
of chromatin
(57–60)
Transcription Telomerase reverse transcriptase, helicases, chromatin-speciﬁc
transcription elongation factor FACT 140kDa subunit,
Transcriptional regulator ATRX, transcription intermediary
factor 1-beta, probable global transcription activator SNF2L1,
transcriptional activator protein Pur-alpha, transcription factor
B1 (mitochondrial), activated RNA polymerase II transcription
cofactor 4 variant, polymerase I and transcript release factor,
Activating signal cointegrator 1 complex subunit 3, DNA-
directed RNA polymerase II 140kDa polypeptide, RUVBL2
protein, EBNA-2 co-activator variant, RHA helicase A, nucleolar
RNA helicase 2, U5 snRNP-speciﬁc 116kDa protein, U5
snRNP-speciﬁc 200kDa protein, hnRNPs, DEAD-box RNA
helicases p72 (DDX17), transcriptional repressor protein YY1,
PARP-9/BAL1, PARP-14/BAL2, PARP-15/BAL3, HMG
proteins, transcription factor SP1, Histone acetyltransferase
p300, histone acetyltransferase PCAF
DNA-directed RNA
synthesis
(24–26,61–71)
Replication Helicases, MCM3, MCM4, MCM5, MCM7, DNA primase, DNA
topoisomerase, DNA polymerase, replication factor C subunit 4,
replication factor C subunit 5, telomerase reverse transcriptase
Synthesis of DNA
strands from a parent
molecule
(2,72)
RNA metabolism,
RNA splicing
and protein
synthesis
Helicases, hnRNPs, SFQP, splicing factor 3B subunit 3, pre-
mRNA-splicing factor SYF1, splicing factor 3B subunit 1,
putative pre-mRNA-splicing factor ATP-dependent RNA helicase
DHX15, splicing factor, arginine/serine-rich 3, RNA-binding
protein PNO1, SF2/ASF-1, pre-mRNA-splicing factor 19,
regulator of nonsense transcripts 1, cytoplasmic FMR1-
interacting protein 1, nuclease sensitive element-binding protein 1,
spliceosome RNA helicase BAT1, mRNA turnover protein 4
homolog, elongation factor 1-alpha 1, elongation factor 2,
polyadenylate-binding protein 1
Pre-mRNA processing,
transport, localization,
mRNA stability
(12,35–38,73–78)
Cell death AIF, hexokinase-1, HKDC1, cell-division cycle and apoptosis
regulator protein 1, deleted in breast cancer gene 1 protein
(DBC-1), BID, Caspase-10, prohibitin, Mitochondrial inner
membrane protein (mitoﬁlin), DEK, death-associated protein
kinase 1/2/3, CAD
Regulation of cell
survival, apoptosis
(24,79–85)
Cell-cycle and mitosis Cell-division cycle and apoptosis regulator protein 1, Cullin-1,
Cullin 4A, CDK1 (Cdc2), CDK2, Aurora-A kinase interacting
protein, Cenp-A,Cenp-B, Cenp-T, spindle assembly checkpoint
protein MAD1, NIMA-related protein kinase Nek10, protein
regulator of cytokinesis 1, BUB3, centrosomal protein of
192kDa, cell-division control protein 6 homolog, cell-division
cycle-associated 7-like protein, cell-cycle checkpoint protein
RAD17, nucleolar and spindle-associated protein 1, CHFR
Progression through cell-
cycle, spindle assembly
and structure, cell-cycle
checkpoints
(6,86–93)
Selected pADPr binding protein candidates revealed from in silico prediction-based or experimental analysis (bold) are proposed for each of
the pathways.
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numbers any other studies that attempted to determine
potential binding partners of pADPr. Moreover, we iden-
tiﬁed several other pADPr-associated proteins that can
either be covalently poly(ADP-ribosyl)ated or noncova-
lent binders of pADPr without matching a typical
pADPr binding motif [e.g. PARP-1, DNA-PK, XRCC5
(Ku86), AIF]. Collectively, these pADPr-associated pro-
teins represent the most comprehensive and detailed infor-
mation related to pADPr binding reported so far.
DISCUSSION
The experimental demonstration of pADPr binding has
traditionally been challenging because of the complexity
of interactions between proteins and pADPr, and because
of the transient nature of the pADPr-mediated biological
response. With technological advances enabling biolog-
ical questions to be addressed proteome-wide, the entire
pADPr interactome is now amenable for scientiﬁc inves-
tigation. This is particularly useful in the context of
poly(ADP-ribosyl)ation, since this phenomenon poten-
tially inﬂuences many diﬀerent cell functions through
molecular interactions with numerous pADPr binding
substrates (summarized in Table 3).
The greatest advantage of a proteome-wide study like
the one presented here lies in the acceleration of the pace
at which pADPr binding candidates are discovered com-
pared with traditional approaches. Although these candi-
dates will require additional validation, their disclosure
opens up considerable opportunity for new hypothesis-
driven experiments.
Our understanding of poly(ADP-ribosyl)ation-related
phenomena should grow more rapidly as studies target
proteins with a putative pADPr binding motif, although
motif prediction presents diﬃculties as matches are not
strictly conserved. Pattern screening remains a valuable
tool to identify interesting targets and their most probable
pADPr binding region. This is especially true if one uses
our reﬁned pADPr binding motif as it generates a more
restricted set of candidates than the original motif and
better correlates with experimentally identiﬁed pADPr-
associated proteins.
We believe that this work represents a valuable inves-
tigation into the pADPr interactome and reveals the poten-
tial of pADPr to impact a wide range of critical biological
functions. By combining bioinformatics-based predictions,
pADPr binding peptide blot assays, two-dimensional
electrophoresis and large-scale LC-MS/MS identiﬁcation
of immunoprecipitated pADPr-associated proteins, this
study represents the ﬁrst large-scale proteomic identiﬁca-
tion of pADPr binding proteins and provides insights into
the pathways that can be modulated by poly(ADP-
ribosyl)ation.
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